The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.
For an income investor holding Pfizer (PFE) stock, which trades around $25 a share, the last five years have posed a sharp question. The company returned an extraordinary $49 billion to shareholders through dividends and buybacks. That figure, equal to 34% of its current market value, is a gusher of cash by any standard. But over that same period, the stock's total return was -21%, while the S&P 500 delivered an +81% gain. The paradox is the whole story: the company showered owners with cash while the stock lagged. Was holding worth it, and is it now?
The machine behind the payout is a large pharmaceuticals business with $63.31 billion in revenue over the last twelve months. Its operating margin of 25% runs well ahead of the 18.4% median for the S&P 500, generating the substantial free cash flow needed to fund shareholder returns. Of the $49 billion returned over five years, the vast majority, $47 billion, came from dividends, with a smaller $2.0 billion spent on share repurchases.
This dividend focus is a core part of the company's stated strategy. Management recently affirmed its commitment, stating on its latest earnings call, "We intend to maintain and over time, grow our dividend as we continue to de-lever and build long-term value." For shareholders, this has meant a steady stream of checks from a business built for scale.
While the checks were generous, the total return figure tells a sobering story. The -21% return already includes reinvested dividends; the stock's price performance was significantly worse. The market has been pricing the stock not on its past cash generation, but on its future challenges. The honest catch is the looming patent cliff, what the industry calls loss of exclusivity (LOE). Management recently sized this headwind at "$14 billion to $15 billion" in annual revenue at risk.
#billion #cash #behind
For an income investor holding Pfizer (PFE) stock, which trades around $25 a share, the last five years have posed a sharp question. The company returned an extraordinary $49 billion to shareholders through dividends and buybacks. That figure, equal to 34% of its current market value, is a gusher of cash by any standard. But over that same period, the stock's total return was -21%, while the S&P 500 delivered an +81% gain. The paradox is the whole story: the company showered owners with cash while the stock lagged. Was holding worth it, and is it now?
The machine behind the payout is a large pharmaceuticals business with $63.31 billion in revenue over the last twelve months. Its operating margin of 25% runs well ahead of the 18.4% median for the S&P 500, generating the substantial free cash flow needed to fund shareholder returns. Of the $49 billion returned over five years, the vast majority, $47 billion, came from dividends, with a smaller $2.0 billion spent on share repurchases.
This dividend focus is a core part of the company's stated strategy. Management recently affirmed its commitment, stating on its latest earnings call, "We intend to maintain and over time, grow our dividend as we continue to de-lever and build long-term value." For shareholders, this has meant a steady stream of checks from a business built for scale.
While the checks were generous, the total return figure tells a sobering story. The -21% return already includes reinvested dividends; the stock's price performance was significantly worse. The market has been pricing the stock not on its past cash generation, but on its future challenges. The honest catch is the looming patent cliff, what the industry calls loss of exclusivity (LOE). Management recently sized this headwind at "$14 billion to $15 billion" in annual revenue at risk.
#billion #cash #behind
2 months ago
